Prestige Consmr Healthcare Inc Stock Price, News & Analysis

Prestige Consumer Healthcare (NYSE:PBH) reported Q2 FY2026 revenue of $274.1M and diluted EPS of $0.86 (adjusted diluted EPS $1.07), with Q2 revenue described as ahead of outlook. Six‑month revenue was $523.6M and adjusted diluted EPS was $2.02. Management reiterated full‑year revenue guidance of $1,100–$1,115M, raised the low end of adjusted diluted EPS to $4.54–$4.58, and maintained free cash flow guidance of $245M+. The company repurchased ~1.1M shares for $75M in Q2 and ~1.6M shares for $109.8M YTD. Net debt was about $0.9B with covenant leverage of 2.4x. Limited Clear Eyes supply was cited as the primary reason for year‑over‑year revenue declines.

Prestige Consumer Healthcare (NYSE:PBH) will release its fiscal 2026 second quarter and first half earnings on Thursday, November 6, 2025 before market open. The company will host a conference call the same morning at 8:30 a.m. ET to discuss results.

Investors can join a live webcast from the Investor Relations page at www.prestigeconsumerhealthcare.com or register to receive dial-in details and a unique PIN for phone participation. A replay of the call will be available on the Investor Relations page for approximately one week after the live event.

Prestige Consumer Healthcare (NYSE:PBH) announced its participation in the upcoming Barclays Global Consumer Staples Conference. The presentation is scheduled for Thursday, September 4, 2025 at 12:45 p.m. ET.

Investors and interested parties can access the live webcast through the company's website under the "Investors" section and "Events and Presentations" tab. A replay of the presentation will be made available on the company's website after the event.

Prestige Consumer Healthcare (NYSE:PBH) reported Q1 fiscal 2026 results with revenue of $249.5 million, down 6.6% year-over-year, primarily due to Clear Eyes supply constraints. The company posted diluted EPS of $0.95, up 6% from the prior year.

In a strategic move, PBH announced the acquisition of Pillar5 Pharma, their current eye care supplier, expected to close in Q3 fiscal 2026. The company revised its fiscal 2026 outlook, lowering revenue guidance to $1,100-$1,115 million from $1,140-$1,155 million, and adjusted EPS guidance to $4.50-$4.58 from $4.70-$4.82.

Despite challenges, the company demonstrated strength in international segment growth, improved gross margins, and generated strong free cash flow of $78.2 million. The company maintains a healthy balance sheet with a covenant-defined leverage ratio of 2.4x.

Prestige Consumer Healthcare (NYSE:PBH) has scheduled its fiscal 2026 first quarter earnings release for Thursday, August 7, 2025, before market opening. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results.

Investors can access the live webcast through the company's Investor Relations webpage at prestigeconsumerhealthcare.com. For phone participation, registration is required to receive dial-in details and a unique pin. A replay of the conference call will be available for approximately one week on the company's IR page.

Medtech Products Inc., a Prestige Consumer Healthcare company, has initiated a nationwide voluntary recall of five lots of Little Remedies® Honey Cough Syrup due to Bacillus cereus contamination and loss of shelf-stability. The affected lots were distributed across the United States through retailers and online from December 2022 through June 2025. The contamination can cause two types of food-borne illnesses, with symptoms including nausea, vomiting, stomach cramps, and diarrhea. While healthy individuals may experience short-term illness, high levels of B. cereus exposure can be fatal. The recall affects 4 FL OZ bottles with specific lot numbers and expiration dates ranging from 11/2025 to 12/2026. No serious adverse events have been reported to date. The company is offering reimbursement for affected products and has established multiple contact channels for consumer inquiries.

Prestige Consumer Healthcare Inc. (NYSE:PBH) announced its participation in the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference. The company will engage in a fireside chat session scheduled for Wednesday, June 11, 2025, at 10:30 a.m. ET. The event will be conducted virtually and will be accessible through a live webcast on the company's website under the "Investors" section and "Events and Presentations" tab. For those unable to attend the live session, a replay option will be made available on the company's website after the event.

Prestige Consumer Healthcare (NYSE:PBH) reported strong financial results for Q4 and fiscal 2025. Q4 revenue reached $296.5M, up 7.0% YoY, with organic growth of 7.9%. Full-year revenue hit $1,137.8M, a 1.1% increase, with organic growth of 1.2%. The company achieved fiscal 2025 diluted EPS of $4.29 and adjusted EPS of $4.52, up 7.4% YoY. Strong performance was driven by International business strength, North American growth across categories, and eCommerce success. GI and Women's Health categories led growth, with notable performance from Summer's Eve, Dramamine, and Fleet brands. The company reduced leverage to 2.4x and repurchased 0.7M shares for $51.5M. For fiscal 2026, PBH projects organic revenue growth of 1-2% and diluted EPS of $4.70-$4.82, despite anticipated $15M headwind from tariff impacts.

Prestige Consumer Healthcare (NYSE:PBH) reported strong financial results for Q4 and fiscal 2025. Q4 revenue reached a record $296.5M, up 7.0% YoY, with organic revenue growth of 7.9%. Full-year revenue was $1,137.8M, a 1.1% increase from FY2024. The company achieved diluted EPS of $4.29 for FY2025, while adjusted EPS grew 7.4% to $4.52. Growth was driven by strong performance in GI and Women's Health categories, led by Summer's Eve, Dramamine, and Fleet brands. The International segment showed robust growth, particularly in Australia with the Hydralyte brand. The company reduced leverage to 2.4x and repurchased 0.7M shares for $51.5M. For FY2026, PBH projects organic revenue growth of 1-2% and diluted EPS of $4.70-$4.82, despite anticipated $15M headwind from inflationary tariff impacts.